Announced

Serum Institute to acquire 15% stake in Biocon Biologics for $734m.

Synopsis

Serum Institute, an Indian biotechnology and biopharmaceuticals company, agreed to acquire 15% stake in Biocon Biologics, an innovation led fully integrated biopharmaceutical company that developes affordable biosimilars, novel biologics & complex APIs, for $734m. “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics. Our shared vision of building large scale businesses having global impact makes it a unique and synergistic value creation opportunity," Kiran Mazumdar-Shaw, Biocon & Biocon Biologics Executive Chairperson.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US